ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

suzetrigine

Also written as “Suzetrigine”, “VX-548” and “SUZ”.

Its studies are mostly in Pain · Acute Pain · Neuralgia · Radiculopathy, led by 2 companies.

Drug pageSuzetrigine: every studyAll 57 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 19, 202527 company-led studies, 3 open or runningNext primary completion: Jan 25, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vertex Pharmaceuticals263 open or runningphase 4since Mar 19, 2025Jul 15, 2021Jan 25, 2027phase 3 · NCT06696443
Latigo Biotherapeuticsits history only10 open or runningearly phase 1since May 6, 2025May 6, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Vertex Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 9 studies since Jul 15, 2021.

  1. Dec 14, 2022Phase 3 study in PainNCT05661734 · 258 enrolled · United States
  2. Jan 19, 2023Phase 1 study in PainNCT05704556 · 38 enrolled · United States
  3. Jan 19, 2023Named suzetrigineINNProposed as its International Nonproprietary Name in WHO's List 128 · before, VX-548
  4. Apr 5, 20232 phase 1 studies in PainNCT05818852, NCT05851157
  5. Dec 10, 2023Phase 2 study in Painful Lumbosacral RadiculopathyNCT06176196 · 218 enrolled · United States
  6. Mar 21, 2024Phase 1 study in PainNCT06336096 · 48 enrolled · United States
  7. May 14, 2024Phase 1 study in PainNCT06420765 · 92 enrolled · United Kingdom
  8. Sep 30, 2024Phase 3 study in Diabetic Peripheral Neuropathic PainNCT06628908 · 1,100 planned · United States
  9. Nov 15, 2024Phase 3 study in Diabetic Peripheral Neuropathic PainNCT06696443 · 455 enrolled · United States
  10. Feb 5, 20252 phase 1 studies in PainNCT06820307, NCT06834009
  11. Mar 19, 20252 phase 4 studies in Acute PainNCT06887972, NCT06887959
  12. Nov 13, 2025Phase 3 study in Diabetic Peripheral Neuropathic PainNCT07231419 · 734 planned · United States
  13. Jan 23, 2026Phase 1 study in PainNCT07378865 · 13 enrolled · United States
  14. Apr 13, 2026Phase 4 study in PainNCT07538570 · 66 enrolled · United States
  15. Apr 29, 2026Phase 1 study in PainNCT07570069 · 18 enrolled · United States

Ahead

  1. Jan 25, 2027Primary completion: phase 3 study in Diabetic Peripheral Neuropathic PainNCT06696443
  2. Apr 6, 2027Primary completion: phase 3 study in Diabetic Peripheral Neuropathic PainNCT07231419
  3. May 31, 2027Primary completion: phase 3 study in Diabetic Peripheral Neuropathic PainNCT06628908

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 26 Vertex Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07570069Pain · United States1CompletedJul 16, 202618
NCT07538570Pain · United States4CompletedOct 12, 202666
NCT07378865Pain · United States1CompletedAug 17, 202613
NCT07231419Diabetic Peripheral Neuropathic Pain · United States3RecruitingApr 6, 2027734
NCT06887972Acute Pain · United States4CompletedOct 24, 2025100
NCT06887959Acute Pain · United States4CompletedOct 27, 202547
NCT06834009Pain · United States1CompletedApr 24, 202510
NCT06820307Pain · United States1CompletedApr 29, 202550
NCT06696443Diabetic Peripheral Neuropathic Pain · United States3Active, not recruitingJan 25, 2027455
NCT06628908Diabetic Peripheral Neuropathic Pain · United States3RecruitingMay 31, 20271,100
NCT06420765Pain · United Kingdom1CompletedMar 22, 202592
NCT06336096Pain · United States1CompletedJun 19, 202448
NCT06176196Painful Lumbosacral Radiculopathy · United States2CompletedOct 2, 2024218
NCT05851157Pain · United States1CompletedOct 30, 202373
NCT05818852Pain · United States1CompletedJun 12, 202372
NCT05704556Pain · United States1CompletedMar 30, 202438
NCT05661734Pain · United States3CompletedDec 12, 2023258
NCT05660538Diabetic Peripheral Neuropathy · United States2CompletedOct 12, 2023194
NCT05635110Pain · Australia1CompletedJun 8, 202331
NCT05560464Pain · United States1CompletedJul 24, 202336
NCT05558410Acute Pain · United States3CompletedAug 25, 20231,118
NCT05553366Acute Pain · United States3CompletedDec 15, 20231,075
NCT05541471Pain · United States1CompletedApr 16, 202337
NCT05455502Pain · United States1CompletedSep 17, 202224
NCT05034952Acute Pain · United States2CompletedDec 5, 2021303
NCT04977336Acute Pain · United States2CompletedFeb 17, 2022274

How it is read

Names in the registry

  • “Suzetrigine”, 13 entries
  • “VX-548”, 11 entries
  • “SUZ”, 2 entries
  • “suzetrigine 100mg”, 1 entry
  • “Suzetrigine (SUZ)”, 1 entry

Codes read as this program: VX548.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.